Howard Capital Management Group LLC Purchases 5,670 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Howard Capital Management Group LLC increased its stake in IQVIA Holdings Inc. by 4.6%, purchasing an additional 5,670 shares to own a total of 128,584 shares, representing 1.4% of its investment portfolio.
• IQVIA recently reported earnings of $2.81 per share, surpassing estimates, with revenues of $4.02 billion, a 5.3% increase year-over-year.
• The stock has received positive analyst ratings, with a consensus of "Moderate Buy" and an average price target of $229.64 from several brokerages, indicating strong market confidence.

Howard Capital Management Group LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 128,584 shares of the medical research company's stock after buying an additional 5,670 shares during the quarter. IQVIA accounts for approximately 1.4% of Howard Capital Management Group LLC's investment portfolio, making the stock its 28th largest position. Howard Capital Management Group LLC owned approximately 0.07% of IQVIA worth $20,264,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. Patton Fund Management Inc. acquired a new position in IQVIA in the 2nd quarter valued at approximately $231,000. Vision Capital Management Inc. increased its holdings in IQVIA by 4.5% in the second quarter. Vision Capital Management Inc. now owns 35,146 shares of the medical research company's stock valued at $5,539,000 after purchasing an additional 1,502 shares during the period. ST Germain D J Co. Inc. raised its position in IQVIA by 136.1% during the 2nd quarter. ST Germain D J Co. Inc. now owns 451 shares of the medical research company's stock worth $71,000 after purchasing an additional 260 shares during the last quarter. CX Institutional lifted its holdings in IQVIA by 104.4% during the 2nd quarter. CX Institutional now owns 1,549 shares of the medical research company's stock worth $244,000 after buying an additional 791 shares during the period. Finally, Dakota Wealth Management bought a new stake in shares of IQVIA in the 2nd quarter valued at about $801,000. 89.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on IQV. Redburn Partners set a $214.00 price target on IQVIA in a research note on Wednesday, September 3rd. Robert W. Baird increased their target price on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Jefferies Financial Group upgraded shares of IQVIA from a "hold" rating to a "buy" rating and boosted their price target for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. Truist Financial upped their price objective on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Finally, UBS Group lifted their target price on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Eighteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $229.64.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Up 1.6%

IQVIA stock opened at $179.51 on Friday. The company has a market capitalization of $30.52 billion, a PE ratio of 25.98, a PEG ratio of 1.94 and a beta of 1.32. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $237.34. The firm's fifty day moving average is $187.01 and its 200 day moving average is $167.28. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business's revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.